LBRX (LB Pharmaceuticals) OCF Margin %: 0.00% (As of Mar. 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.64
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals OCF Margin %?

LB Pharmaceuticals LBRX +2.26% 12 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 957 Biotechnology companies, LB Pharmaceuticals ranks worse than 104493.1% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. LB Pharmaceuticals's Cash Flow from Operations for the three months ended in Mar. 2026 was $-23.29 Mil. LB Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, LB Pharmaceuticals's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, LB Pharmaceuticals's current OCF Yield % is -5.38%.

The historical rank and industry rank for LB Pharmaceuticals's OCF Margin % or its related term are showing as below:


LBRX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

LB Pharmaceuticals OCF Margin % Related Terms

LB Pharmaceuticals OCF Margin % Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals OCF Margin % Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
OCF Margin %
0.00 0.00 0.00 0.00

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

LB Pharmaceuticals's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-35.208/0
= %

LB Pharmaceuticals's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-23.29/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
LB Pharmaceuticals (LBRX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on LB Pharmaceuticals and its competitors. According to the industry distribution chart, LB Pharmaceuticals ranks #999999 out of 957 companies in the Biotechnology industry.
Is LB Pharmaceuticals' OCF Margin % too high?
LB Pharmaceuticals' current OCF Margin % is 0.00%. Based on the distribution chart, LB Pharmaceuticals ranks #999999 out of 957 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' OCF Margin % compare to MRVI and SLDB?
According to the Biotechnology industry distribution chart, LB Pharmaceuticals ranks #999999 out of 957 companies for OCF Margin %. This places LB Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.64
Price